IL1A and cancer: In summary, both preclinical and clinical investigations are needed with the aim to validate these findings in the clinical setting, to unravel the underlying mechanism which contributed to the reduced incidence of malignant disease and to identify suitable treatment strategies for the application of IL-1 blocking agents in different cancer entities.